Abstract
Timely detection of Barrett’s esophagus, the pre-malignant condition of esophageal adenocarcinoma, can improve patient survival rates. The Cytosponge-TFF3 test, a non-endoscopic minimally invasive procedure, has been used for diagnosing intestinal metaplasia in Barrett’s. However, it depends on pathologist’s assessment of two slides stained with H&E and the immunohistochemical biomarker TFF3. This resource-intensive clinical workflow limits large-scale screening in the at-risk population. Deep learning can improve screening capacity by partly automating Barrett’s detection, allowing pathologists to prioritize higher risk cases. We propose a deep learning approach for detecting Barrett’s from routinely stained H&E slides using diagnostic labels, eliminating the need for expensive localized expert annotations. We train and independently validate our approach on two clinical trial datasets, totaling 1,866 patients. We achieve 91.4% and 87.3% AUROCs on discovery and external test datasets for the H&E model, comparable to the TFF3 model. Our proposed semi-automated clinical workflow can reduce pathologists’ workload to 48% without sacrificing diagnostic performance.
Competing Interest Statement
Maria O'Donovan is named on patents related to Cytosponge that have been licensed to COVIDien (now Medtronic). Sarah Killcoyne, Sumanth Murthy, and Maria O'Donovan are employees of Cyted Ltd that provides the diagnostic testing for the Cytosponge product. Marcel Gehrung is a co-founder and CEO of Cyted Ltd.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the DELTA study, ethics approval was obtained from the East of England - Cambridge Central Research Ethics Committee (DELTA 20/EE/0141) and written informed consent was obtained from each patient. For the BEST2 study, ethics approval was obtained from the East of Englan - Cambridge Central Research Ethics Committee (BEST2 10/H0308/71) and the trials are registered in the UK Clinical Research Network Study Portfolio (9461). Written informed consent was obtained from each patient.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
List of Acronyms
- AUPR
- area under precision–recall curve
- AUROC
- area under receiver operating characteristic curve
- BE
- Barrett’s esophagus
- CI
- confidence intervals
- CNN
- convolutional neural network
- DAB
- 3,3’-diaminobenzidine
- EAC
- esophageal adenocarcinoma
- FN
- false negative
- FP
- false positive
- GERD
- gastroesophageal reflux disease
- H&E
- hematoxylin and eosin
- IM
- intestinal metaplasia
- MIL
- multiple instance learning
- ML
- machine learning
- MLP
- multi-layer perceptron
- Swin-T
- Shifted Window Transformer
- TFF3
- trefoil factor 3
- WSI
- whole-slide image